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Previewscells and their priming by antigens and
raises additional questions. The new
functions of Bach2 and PI3K-AKT-mTOR
signaling suggest pathways to plasma
cell differentiation, but how are these
mechanisms linked with cytoplasmic
tails of IgG? As the authors point out, the
IgG1 tail may facilitate Bach2 down-
regulation. PI3K-AKT-mTOR signaling
could be qualitatively and/or quantita-
tively enhanced by the IgG tail. In addition,
are other genes involved? Horikawa
et al. (2007) have demonstrated extensive
changes in gene expression resulting
from BCR signaling by the IgG tail. These
data suggest that additional differences in
signaling remain to be elucidated.
Bach2 is also important for differen-
tiation in T cells (Roychoudhuri et al.,
2013). Targeted deletion of Bach2 dem-onstrates its immunoregulatory role in
T cell development. Bach2 represses
effector programs in multiple CD4+ T cell
subsets, including regulatory T cells.
Clearly, further investigation is needed to
understand the scope of Bach2’s func-
tions in B cells as well as T cells. In the
meantime the present study reveals that
as in the labor market, so follows plasma
cell differentiation: experience matters!REFERENCES
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The tyrosine phosphatase PTPN22 regulates T cell receptor signaling. In this issue of Immunity, Wang et al.
(2013) show that inmyeloid cells PTPN22 potentiates TLR-induced type I interferon production and that auto-
immunity-associated allele PTPN22W encodes a reduced-function variant.Protein tyrosine phosphatase nonrecep-
tor type 22 (PTPN22, also termed Lyp
and encoded by PTPN22) is preferentially
expressed in hematopoietic and immune
cells. The role of PTPN22 and its murine
ortholog Ptpn22 (also termed PEP and
encoded by Ptpn22) has attracted intense
investigation because allelic variants of
PTPN22 have been identified as one of
the strongest genetic risk factors for a
variety of autoimmune diseases, including
type I diabetes, rheumatoid arthritis (RA),
systemic lupus erythematosus (SLE), Ha-
shimoto’s thyroiditis, and Graves disease
(Burn et al., 2011; Zheng et al., 2012). The
autoimmune disease-associated risk
allele of PTPN22 encodes a substitutionof tryptophan (W) for arginine (R) at
position 620 (R620W) and is termed
PTPN22W, whereas the nonrisk allele is
PTPN22R. Many PTPN22W-associated
diseases are characterized by dysregu-
lated adaptive immunity and autoanti-
body production.
PTPN22 is expressed in many immune
cell types, including T cells, B cells, natu-
ral killer cells, dendritic cells (DCs), and
monocytes and macrophages (reviewed
in Burn et al., 2011). Full-length PTPN22
contains 807 amino acid residues and
several functional domains, including an
amino-terminal catalytic domain and
carboxy-terminal proline-rich motifs,
including a PLPXR motif termed P1 thatharbors the R620W substitution and can
mediate interactions with SH3-containing
proteins. Identified substrates for PTPN22
include multiple activating signaling
molecules such as Src family kinases,
Syk and ZAP70, T cell receptor com-
ponents CD3ε and TCRz, and the E3 ubiq-
uitin ligase Cbl. Although experimental
differences have not been fully recon-
ciled, the preponderance of evidence
indicates that PTPN22 and its murine
ortholog Ptpn22 function as negative reg-
ulators of TCR signaling (Figure 1) and
suggests that PTPN22W represents a
gain-of-function allele with increased
phosphatase activity that attenuates

























Figure 1. Different Mechanisms of PTPN22 Action in T Cells and Myeloid Cells
In T lineage cells, PTPN22 negatively regulates T cell receptor (TCR) signaling. PTPN22 dephosphorylates
and thereby inactivates signaling intermediates such as immunoreceptor tyrosine-based activation motifs
(ITAMs) and tyrosine kinase ZAP-70. PTPN22 interacts with Csk via the P1 proline rich motif PLPXR
(shown as yellow dot) whose sequence is altered to PLPXW in autoimmune disease-associated variant
PTPN22W. The R620W substitution in PTPN22W destabilizes interactions with Csk and results in
increased phosphatase activity (not depicted). In myeloid lineage cells, PTPN22 modulates TLR, and
possibly TNFR, signaling by interacting with TRAF3 to augment activating lysine 63-linked ubiquitination
and thus increase IRF3 and IRF7 activation and type I IFN production. The PTPN22W variant results in
lower TRAF3 activation and diminished IFN production (not depicted). Altered interactions of PTPN22W
with TRAF3 may also affect Jnk-p38 and noncanonical NF-kB signaling leading to activation of p52 and
Rel B.
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Previewspredispose to autoimmunity by de-
creasing negative selection or by de-
creasing differentiation into regulatory
rather than effector T cells. It has been
difficult to resolve how a change in amino
acid residue 620, which is distant from the
catalytic domain, affects PTPN22 enzy-
matic function. The most likely explana-
tion is that the R620W substitution
weakens the interaction of PTPN22 with
the kinase Csk, with an attendant in-
crease in PTPN22 activity (Fiorillo et al.,
2010).
The majority of previous work has
focused on the role of PTPN22 in lympho-
cytes and on its enzymatic function as a
phosphatase (Burn et al., 2011). The study
by Wang et al. in this issue of Immunity
(Wang et al., 2013) investigated the role
of Ptpn22 and the functional conse-
quences of the R620W substitution in
PTPN22 in TLR-induced responses in
macrophages and DCs. By using com-
plementary biochemical and genetic
approaches with Ptpn22/ mice, the
authors provide compelling evidence
that Ptpn22 is required for full induction
of type I interferons (IFNs) in response to
various TLR ligands but is dispensable
for induction of inflammatory cytokines.92 Immunity 39, July 25, 2013 ª2013 ElsevieThe Ptpn22-dependent component of
the type I IFN response was biologically
important because it was required for full
antigen-induced CD8+ T cell expansion
when IFN-inducing poly(IC) was used as
adjuvant and for antiviral responses
in vivo. Interestingly, Ptpn22 was required
for poly(IC)-induced suppression of
arthritis and CpG-induced suppression
of dextran sodium sulfate (DSS)-colitis;
protection in both models is mediated by
type I IFNs whose production was attenu-
ated by Ptpn22 deficiency (Katakura
et al., 2005; Yarilina et al., 2007). The
protective effect on arthritis occurred
independently of lymphocytes, further
supporting the functional importance of
PTPN22 in myeloid cells. Mechanistic
experiments showed that Ptpn22 associ-
ates with the TLR-activated signaling
molecule TRAF3 to promote its activation
via K63-linked polyubiquitination and thus
activation of downstream IRF3 and IRF7
and IFN production (Figure 1). Strikingly,
Ptpn22 promoted TLR-mediated type I
IFN production independently of its enzy-
matic function as a phosphatase.
These results establish the importance
of Ptpn22 in a new cell type (myeloid
cells), identify a key new function of pro-r Inc.moting type I IFN induction, and suggest
a new molecular mechanism of Ptpn22
action independent of its phosphatase
activity. However, interpretation of these
results and their relevance for human
autoimmunity are subject to several
caveats: (1) Most of the aforementioned
results were obtained in murine systems,
but because PTPN22 (Lyp) and Ptpn22
(PEP) are only 60% homologous in their
noncatalytic regions, it is not clear how
these results translate to the role of
human PTPN22. (2) The loss of function
artificially created by deletion of Ptpn22
is complete and it is not clear how accu-
rately results obtained when Ptpn22 is
absent mirror the more subtle effects of
the PTPN22W variant. (3) Removal of
the Ptpn22 protein will alter the composi-
tion Ptpn22-containing signaling com-
plexes and thus the function of proteins
contained in these complexes; such
effects may not occur in cells that
express PTPN22W. The authors resound-
ingly address these caveats by using a
transgenic approach to reconstitute
Ptpn22/ mice with human PTPN22R or
PTPN22W. Murine Ptpn22-deficient DCs
and macrophages expressing PTPN22R
produced more IFN (but not tumor necro-
sis factor, TNF) than did cells expressing
PTPN22W. Accordingly, expression of
the PTPN22R transgene resulted in
greater TLR-induced expression of IFNs
and IFN-stimulated genes (ISGs) in vivo,
and PTPN22R was more effective than
PTPN22W in mediating poly(IC)-induced
suppression of inflammatory arthritis.
Corroborating results obtained in the
transgenic system, primary human
PBMC from healthy donors who carried
the risk variant PTPN22W exhibited
lower induction of type I IFNs and ISGs
after LPS stimulation than did donors
homozygous for PTPN22R. Thus,
PTPN22W exhibits reduced function in
the most appropriate context of primary
human cells from healthy individuals.
Mechanistically, PTPN22W showed
decreased association with TRAF3,
which was associated with decreased
TRAF3 K63-linked polyubiquitination
and could explain diminished IFN pro-
duction. These results clearly establish
that human PTPN22W functions as a
hypomorphic allele in macrophages and
DCs, with attendant diminished IFN
production and IFN responses on TLR
stimulation.
Immunity
PreviewsThe study by Wang et al. highlights the
importance of PTPN22 in innate immune
TLR-IFN-mediated responses but raises
questions about mechanisms by which
a hypomorphic allele that results in lower
type I IFN production can promote auto-
immunity. The authors observed that
PTPN22 was important for increasing
type I IFN production in response to
exogenous ligands that activate TLR3,
Mda5, and TLR9, which is protective in
K/BxN serum-induced arthritis and
DSS-induced colitis (Katakura et al.,
2005; Yarilina et al., 2007). These are
acute induced models of the inflamma-
tory effector phase of disease that occurs
mostly independently of autoimmunity. In
these models, type I IFNs likely target
myeloid lineage cells and possibly
nonimmune tissue cells to suppress pro-
duction and function of inflammatory
mediators such as interleukin-1 (IL-1)
(Katakura et al., 2005; Prinz et al., 2008;
Yarilina et al., 2007). Thus, this work sug-
gests that loss of function of PTPN22 in
myeloid cells can result in an augmented
inflammatory effector phase of autoim-
mune diseases. Although suppression of
inflammation by type I IFNs, and thus
the role of PTPN22, is striking in these
models, therapy with type I IFNs exhibits
limited efficacy in human rheumatoid
arthritis and inflammatory bowel disease
(IBD) (reviewed in Kalliolias and Ivashkiv,
2010). This raises questions about the
importance of this IFN-mediated sup-
pressive mechanism in human diseases.
An alternative, albeit at this point specu-
lative, pathogenic mechanism is that
diminished IFN production can compro-
mise host defense and lead to uncon-
trolled infections that trigger autoimmu-
nity. Another question is why diseases
characterized by a strong innate immune
component, such as IBD and ankylosing
spondylitis, are not associated with
PTPN22W, which instead is associated
with increased susceptibility to diseases
characterized by dysregulation of adap-
tive immunity and autoantibody produc-
tion, such as type I diabetes, RA, SLE,
Graves disease, and ANCA-associated
vasculitis (Burn et al., 2011). Because
type I IFNs generally promote adaptive
immunity and antibody production,
decreased IFN production associated
with the loss-of-function PTPN22W allele
described in Wang at al. would be
expected to have the opposite effect;namely, decreased autoimmunity. This
paradox could be explained if recently
described immunosuppressive effects of
type I IFNs in chronic infections are also
important in autoimmune diseases.
Furthermore, if the findings of Wang
et al. reflect the major contribution of
PTPN22W to disease susceptibility, one
would predict that PTPN22W (and thus
low IFN production) would be associated
with diseases such as multiple sclerosis
(MS) where IFNs are protective, whereas
PTPN22R (high IFN production) would
be associated with diseases where IFNs
are likely pathogenic, such as SLE (Kallio-
lias and Ivashkiv, 2010). Contrary to these
predictions, PTPN22W is not associated
with MS, whereas it is apparently para-
doxically associated with SLE (Burn
et al., 2011; Zheng et al., 2012). The domi-
nant paradigm of SLE pathogenesis
posits that SLE is driven by excessive
signaling by TLRs leading to increased
type I IFN production, with downstream
increased autoimmunity and autoanti-
body production (Kalliolias and Ivashkiv,
2010). Possible explanations for the asso-
ciation of PTPN22W with SLE are as
follows: (1) PTPN22W plays a pathogenic
role in a nonmyeloid cell type, for example
by altering TCR or BCR signaling,
and relatively diminished TLR-induced
IFN production in patients harboring
PTPN22W is still sufficient to promote
disease. (2) A relative deficit in IFN pro-
duction facilitates subclinical or chronic
infections that trigger autoimmunity. (3)
PTPN22W expression in myeloid cells
triggers a pathogenic mechanism that re-
mains to be discovered. In this scenario,
the true pathogenic consequences of
decreased PTPN22W-TRAF3 interactions
would not be related to IFN production
but to other TRAF3-mediated signaling
events, for example, increased activation
of MAPKs or noncanonical NF-kB
signaling (Figure 1) (Ha¨cker et al., 2011).
A more extensive investigation of this
possibility than performed in Wang et al.,
for example by gene expression profiling,
could be instructive. Equally importantly,
TRAF3 is also a key mediator of signaling
by TNF family cytokines (Figure 1),
including TNF-a, a key pathogenic factor
in several PTPN22W-associated diseases
such as RA, psoriatic arthritis, ANCA-
associated vasculitis, and inflammatory
myopathies. Thus, investigation of the
role of PTPN22 in TNFR responses,Immunincluding the recently described crosstalk
between TNF-a and IFN responses (Gor-
don et al., 2012 and references therein),
may provide additional insights about
pathogenic mechanisms related to
PTPN22W.
In summary, the study by Wang at al.
identifies a new function for PTPN22—
regulation of IFN production in innate
immune cells—and a new molecular
mechanism of PTPN22 action via regula-
tion of TRAF3 ubiquitination rather than
dephosphorylation of signaling interme-
diates. This work also establishes that
the autoimmune disease-associated
PTPN22W is a hypomorphic allele in the
context of TLR-stimulated IFN produc-
tion in innate immune cells. These find-
ings highlight the importance of studying
function of disease-associated variants
in different cell types and open new lines
of investigation of PTPN22 function and
mechanisms of action. The study by
Wang at al. also raises thought-provok-
ing questions about how PTPN22W in-
creases susceptibility to autoimmune
diseases.REFERENCES
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